Lansinoh launches breast pump, baby bottle and nonmedicinal pain reliever for breast-feeding moms
WASHINGTON — Lansinoh Laboratories on Friday announced the launch of the new Lansinoh Affinity Pro Double Electric Breast Pump, featuring three customizable pumping styles that can help moms maximize milk flow and comfort to enhance breastfeeding success. The new Lansinoh Affinity Pro pump was recognized as a finalist in the Juvenile Products Manufacturers Association 2012 Innovation Awards, the company reported.
“What’s most amazing about this pump is that it actually has the potential to help more moms have greater success in breastfeeding," stated Michael Barclay, SVP marketing at Lansinoh. "By combining the Affinity Pro with our new Lansinoh Momma Bottle with NaturalWave Nipple, the Lansinoh TheraPearl 3-in-1 Breast Therapy and our cornerstone Lansinoh HPA Lanolin, moms can have a comprehensive solution for maximizing their breastfeeding success.”
The new Affinity Pro features an LCD screen that helps moms keep track of pumping time. Also, unlike other leading brands of breast pumps, the Lansinoh Affinity Pro is a closed system, which ensures maximum hygienic milk conditions for babies by preventing bacteria and mold growth in tubing and the pump motor. The unit will begin shipping in 2013 and will retail at a suggested $129.99.
Lansinoh also recently launched its Lansinoh Momma Bottle with NaturalWave Nipple, which allows for an easy transition from the breast to the bottle and back. The nipple has been proven to help babies utilize the same physical actions as when feeding at the breast, reducing the potential for “artificial nipple preference” that can interrupt and derail breastfeeding.
Also new is the Lansinoh TheraPearl 3-in-1 Breast Therapy — gel packs that conform to the breast and provide 360-degree relief to help address breastfeeding-related challenges so moms can breastfeed longer. The 3-in-1 provides relief for breastfeeding moms in three ways: 1) heat therapy — to help reduce pain and conditions of mastitis and clogged ducts; 2) cold therapy — to help reduce the pain and discomfort associated with engorgement, which can occur during breastfeeding; and 3) hot/warm therapy — to use in conjunction with a pump to help with let-down, which maximizes milk flow so moms can reduce pumping time.
Nipro Diagnostics garners Consumer Reports recommendation for the second consecutive year
NEW YORK — Nipro Diagnostics’ TRUEresult Blood Glucose Meter for the second consecutive year received a “recommended“ rating from Consumer Reports as part of the publication’s review of blood glucose meters in its October issue.
The TRUEresult meter received an “excellent” rating for accuracy and “very good“ for repeatability and convenience. Additionally, the TRUE2go meter rated “very good” for accuracy and repeatability, and “good” for convenience.
“Results like these demonstrate our belief that the blood glucose monitoring systems we produce are not just equal, but even superior in performance when tested against specific national brands,” stated Scott Verner, Nipro president and CEO. “Nipro Diagnostics provides products that deliver exceptional outcomes at highly affordable prices, and we’ve proven our ongoing commitment to both reducing costs for patients and lowering the overall cost of healthcare. Recognition such as this validates that we go above and beyond these objectives.”
FDA petitions appellate court to revisit tobacco decision restricting government graphic-image mandate
SILVER SPRING, Md. — The Food and Drug Administration took the Family Smoking Prevention and Tobacco Control Act of 2009 one step closer to being considered by the Supreme Court earlier this week. The FDA recently petitioned the D.C. Circuit Court of Appeals to revisit the court’s August decision that ruled in favor of the tobacco industry and precluded the FDA from mandating that graphic images depicting the consequences of smoking be placed on all cigarette packaging.
"The government’s interest in effectively communicating the health risks of smoking cannot be overstated," the agency argued, noting that the magnitude of the public health harm is nicotine addiction and that most smokers become hooked prior to their 18th birthday. "Children and adolescents, unable to assess the addictiveness and consequences of smoking, dominate the ranks of new smokers," the agency stated. "The evidence before Congress and the voluminous literature reviewed in the FDA rulemaking establish that cigarette health warnings with graphics are far more effective in communicating health-risk information than are health warnings with text alone."
Hyman, Phelps & McNamara, which publishes a blog regarding the FDA, posted a complete copy of the FDA’s filing here.